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Medical staff need to be aware of major incident planning
Editor—Last month the BMA warned that
too few people in the United Kingdom
know how to respond to a terrorist attack.1
Its concerns about too few senior officials
being aware of plans and recommendations
to improve preparedness are sensible, but
we believe that not enough medical staff are
aware of their role in the event of a terrorist
attack.
We recently carried out a survey in the
largest acute NHS trust of the south west of
England to assess medical staff’s knowledge
about the local major incident plan. We sent
questionnaires to the 107 doctors in North
Bristol NHS Trust with a potential role in
the mobile medical team if they were on
duty during a major incident.
Seventy seven doctors replied (72%).
Sixty nine were aware of the existence of the
local major incident plan, but only 26 had
read part or all of it. Only 11 of the respond-
ing doctors were aware of their potential
role in the mobile medical team. Of these 11
doctors, only three thought themselves
adequately trained for this position, and all
three had been trained as medical incident
officers.
Last year’s National Audit Office report
highlighted deficiencies in NHS plans to
deal with major incidents in England.2 It rec-
ommended upgrading training arrange-
ments. Five months later some doctors are
still unaware of their roles in the event of a
terrorist attack. As a trust we are currently
considering several measures to improve on
our results. We suspect, however, that our
findings are not unique and encourage
other acute trusts to look closely at their
staff’s knowledge and training and act
accordingly.
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Contraindications to use of
metformin
Age and creatinine clearance need to be
taken into consideration
Editor—Jones et al criticise current guide-
lines highlighting possible contraindications
to the use of metformin as too vague and
potentially leading to underuse in patients
with type 2 diabetes.1 Although their desire
for a “less ambiguous” approach seems sen-
sible, their own guidelines still lack clarity.
They note that any specific value of
serum creatinine concentration chosen as a
cut-off point for prescribing metformin will
be arbitrary because of variations in muscle
mass and protein turnover. Despite this they
then select—for undefined reasons—a serum
creatinine value of 150 mol/l as the cut-off
point in their guideline. They then say that
caution should therefore be used in pre-
scribing metformin for elderly patients.
This is a vague statement, which could
be interpreted as meaning that metformin
should not be prescribed at all for elderly
people, that specialist opinion should be
sought or creatinine clearance calculated
before it is prescribed, or that renal function
or serum lactate concentration should be
monitored after it is prescribed.2 In addition,
the authors do not define elderly.
Given that the growing majority of
patients with type 2 diabetes are over 65 and
that there is already evidence of undertreat-
ment in such patients,3 it seems particularly
desirable to be as clear as is possible about
this age group if the full benefits of
treatment are to be attained.
Although the simple formulas that can
be used to estimate creatinine clearance are
not completely reliable,4 it may be preferable
for prescription to be related to such a
calculated estimate of clearance, which takes
into account a patient’s age, rather than the
serum creatinine value alone.
Andrew T Elder consultant physician
Western General Hospital, Edinburgh EH4 2XU
andrew.elder@luht.scot.nhs.uk
Competing interests: None declared.
1 Jones GC,Macklin JP, Alexander WD. Contraindications to
the use of metformin. BMJ 2003;326:4-5. (4 January.)
2 Chehade JM, Mooradian AD. Drug therapy: current and
emerging agents. In: Sinclair AJ, Finucane P, eds.Diabetes in
old age. Chichester: Wiley, 2001:202-3.
3 Hendra TJ, Sinclair AJ. Improving the care of elderly
diabetic patients; the final report of the St Vincent Joint
Task Force for Diabetes. Age Ageing 1997;26:3-6.
4 Cockcroft DW, Gault MH. Prediction of creatinine
clearance from serum creatinine.Nephron 1976;16:31.
Metformin may be useful in gestational
diabetes
Editor—The editorial by Jones et al on
contraindications to the use of metformin
did not mention pregnancy.1 Insulin is
usually recommended in women with
pregestational type 2 diabetes or gestational
diabetes who require drug treatment. Given
that pregnancy is a state of insulin
resistance, metformin might be a logical
alternative.
Cohort data support use of metformin
in pregnancy.2 In a report about women with
polycystic ovary syndrome who conceived
while taking metformin, continuation of
treatment through pregnancy reduced the
incidence of gestational diabetes.3 One
retrospective study has reported an
increased rate of pre-eclampsia in pregnant
women treated with metformin, but it is
weakened by the lack of matched controls.4
The perinatal losses reported in the
metformin group cannot be attributed to
metformin treatment.
We recently completed a pilot study in 30
women with gestational diabetes diagnosed
by the criteria of the Australasian Diabetes in
Pregnancy Society (ADIPS). The women were
randomised to metformin or insulin treat-
ment. They were matched for age, parity,
body mass index, and gestation at entry
(table). The study had ethics approval, and the
women gave written informed consent.
The outcome measure of fetal  cell
activity, assessed by cord C-peptide concen-
tration, was not different in the two groups
(P=0.31; Mann-Whitney test; cord blood was
stored from 17 women). Perinatal outcomes
were not different (table), but numbers are
too small to comment further.5
A larger trial has been started (the
metformin in gestational diabetes (MiG)
study). It has adequate power to test the
hypothesis that metformin treatment com-
pared with insulin in gestational diabetes
will have similar perinatal outcomes,
improve insulin sensitivity in both mother
and baby, and be associated with improved
treatment acceptability. Ethics approval has
been obtained, and recruitment has started.
A follow up study of the offspring will inves-
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tigate potential effects of metformin in rela-
tion to later insulin sensitivity and subse-
quent health.5
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Blanket banning of metformin two days
before surgery may not be a good idea
Editor—The editorial by Jones et al makes
several recommendations about improving
the prescription of metformin.1 It is a pity
that they advised stopping metformin two
days before general anaesthesia when there
is no evidence to suggest that this is
warranted or even safe.
We conducted aMedline search using the
keywords “metformin,” “an(a)esthesia,”
“an(a)esthetics,” “pre-operative,” and
“diabetes.” We found no evidence supporting
the unreferenced statement in their editorial.
Jones et al point out that tissue hypoxia
is commonly the trigger for metformin asso-
ciated lactic acidosis and that metformin has
a short half life except in advanced renal
failure. It follows that it is illogical to suspend
metformin earlier than the evening before
most surgery unless a degree of tissue
hypoxia already exists.
Avoiding metformin in patients with
established or expected tissue hypoxia, or
when substantial impairment of hepato-
renal function perioperatively may be antici-
pated, is perfectly sensible. May we suggest
the recommendations reflect this? Emer-
gency surgery, cardiac surgery, operations
requiring deliberate hypotension, and major
vascular surgery would be examples where
this modified advice would apply.
Much elective surgery, however, does not
fit this description, and the recommendation
by Jones et al will, necessarily, only be appli-
cable to patients undergoing elective sur-
gery. A blanket recommendation to stop
metformin two days before going to theatre
is not necessary, safe, or practical.
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Authors’ reply
Editor—Our aim was to maximise the use
of metformin in patients, in whom it would
improve cardiovascular risk, using a prag-
matic set of guidelines. Although the United
Kingdom prospective diabetes study does
not include patients aged over 65,1 we did
not intend to prohibit metformin use in this
age group.
Metformin does not affect lactate con-
centrations or turnover in elderly patients2
and, unlike insulin or sulphonylureas, does
not cause hypoglycaemia, which can be
problematic in older patients. Although, as
we stated, a creatinine cut-off point of 150
mol/l is arbitrary, it is in keeping with
guidelines from the Scottish Intercollegiate
Group Network and the National Institute
for Clinical Excellence for timing of referral
for specialist opinion of type 2 diabetic
patients with renal disease.3 4 Any cut-off
point based on a calculated creatinine clear-
ance would be equally arbitrary.
Although there are good theoretical
reasons why metformin may be useful in
gestational diabetes and pregnant type 2
diabetic patients, its safety is yet to be estab-
lished. The pilot data of Hague et al show an
increase in caesarean births, neonatal
hypoglycaemia, and need for special care
nursery in the metformin group. It will be
interesting to see if these trends persist in an
adequately powered study.
We agree with Jones and Yates that
evidence on the safety of metformin around
the time of surgery is lacking. Their
recommendations are helpful. Contrast
media containing iodine rarely cause renal
failure5—and, in a similar way, it may be
overcautious to withdraw metformin after
exposure to contrast media. None the less,
prescribers could be open to criticism if they
do not stop metformin treatment when
there is even a risk of tissue hypoxia.
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Increase in resources should
lead to reduced waiting times
Editor—Although highly topical, the paper
by Martin et al on NHS waiting lists
Baseline characteristics and outcome data in women with gestational diabetes receiving insulin or
metformin. Values are means (SD) unless stated otherwise
Characteristic Insulin (n=14) Metformin (n=16)
Maternal age (years) 34.1 (3.70) 33.7 (4.44)
Median parity (range) 1 (0-5) 1 (0-4)
Maternal weight at trial entry (kg) 101.2 (22.01) 104.4 (22.28)
Maternal body mass index at trial entry 37.9 (6.87) 39.5 (6.94)
Gestation at diagnosis of gestational diabetes (weeks) 27.6 (3.80) 25.8 (5.51)
Blood glucose (glucose tolerance test) (mmol/l)
Fasting 5.4 (0.52) 5.6 (1.26)
2 h 9.4 (1.42) 10.0 (2.07)
Gestation at entry into trial (weeks) 30.4 (4.67) 29.8 (4.49)
No (%) with vaginal delivery 11 (79) 5 (31)
No (%) with induction of labour 9 (64) 5 (31)
No (%) with elective caesarean section 2 (14) 8 (50)
No (%) with emergency caesarean section 1 (7) 2 (13)
No (%) with pre-eclampsia 2 (14) 3 (19)
Gestation at delivery (weeks) 38.2 (1.0) 37.8 (1.5)
Birth weight (g) 3450 (510) 3560 (50)
No with birth weight >4000 g 2 2
Median cord C-peptide (range) (No) (pmol/ml) 0.66 (0.45 – 1.71) (7) 0.53 (0.35 – 2.86) (10)
Cord glucose (mmol/l) (No) 4.2 (1.1) (11) 4.2 (1.9) (14)
Cord glucose/C-peptide 5.7 (2.67) 7.4 (1.69)
No of neonates with intravenous dextrose 1 4
Median time in special care nursery (range) (h) 24 (0-102) 48 (0-360)
No of neonates with jaundice 6 3
No of neonates receiving phototherapy 0 2
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illustrates the misleading policy signals that
can emerge from an inadequate analytic
method.1 The paper finds little and incon-
sistent support for associations of prolonged
waiting times with markers of capacity, inde-
pendent sector activity, or need in the surgi-
cal specialties examined. Hard pressed
policy makers might therefore infer that
increased resources will not ameliorate the
problem of NHS waiting times.
Yet an emerging economic literature,
to which the authors do not refer, indicates
the reverse. The key problem is that the
waiting phenomenon may be the result of a
subtle interaction between the demand for
and supply of surgical capacity. Conse-
quently, contemporary associations
between capacity and waiting time will
reflect a jumble of influences on demand
and supply. A model is required that
enables analysts to disentangle the effects of
demand and supply.
Applying these principles to two years’
data from the English hospital episode
statistics database, we found that supply is
indeed influenced by waiting times.2 Our
findings have since been replicated on a
longer time series of data and for separate
services.3 They are also supported by a time
series analysis of waiting list KH07 data.4
The implication of this work is that a perma-
nent increase in NHS resources will contrib-
ute to a reduction in waiting times, other
things being equal.
Martin et al outline some of the
limitations of their study, and we, too,
acknowledge that our work has its own
shortcomings. However, simple cross sec-
tional associations between waiting time and
various other factors are far too flimsy a
basis from which to make policy inferences,
particularly when there is clear evidence that
the waiting phenomenon reflects both the
pressures of demand and supply.
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New structures of governance
are needed
Editor—Klein sees the “cacophony of
accountabilities” for new NHS foundation
hospitals as a weakness,1 but I would argue
that it may be their greatest strength.
For half a century, the NHS has been
organised as an administrative bureaucracy
led from Whitehall, and the many structural
reforms of the past two decades have done
nothing to change this. No other major pub-
lic service is so centralised. This bureaucracy
has struggled in recent years to absorb
increased resources and to deliver improved
performance, and the difficulties of running
this £70bn organisation by administrative
diktat from Richmond House have become
painfully apparent.
Foundation hospitals offer a vision of a
new model of governance and accountabil-
ity in the NHS, replacing a vertical hierarchy
topped by the Department of Health with a
network of more autonomous healthcare
providers still working within the values,
standards, and requirements of the NHS.2
Foundation hospitals will have a network of
accountability relations with their local com-
munities, local government, other NHS
organisations, national regulators, and the
Department of Health. Plurality will replace
the department’s current, unhealthy
monopoly of control.
Although the government’s guidance
on the practical details of foundation hospi-
tals still needs work,3 the principle seems to
have been accepted across the political spec-
trum. It does not make political, financial, or
organisational sense to try to run the NHS
from the Department of Health in White-
hall, and new structures of governance are
needed that will make NHS organisations
more accountable to the communities they
serve.
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Drug treatment of hypertension
Conclusion of editorial is somewhat
flawed
Editor—In his analysis of the major results
of the recently published antihypertensive
and lipid lowering treatment to prevent heart
attack trial (ALLHAT), Williams concludes
that the key message from this trial is that
what matters most is getting blood pressure
controlled and that this is overwhelmingly
more important than the means.1 2
ALLHAT showed that all blood pressure
drugs were not “created” equally.2 Williams
correctly points out important differences in
the secondary cause specific end points
between chlorthalidone and its active com-
parators: doxazosin (increased congestive
heart failure), lisinopril (increased stroke
and coronary end points), and amlodipine
(increased stroke). For this very reason, the
data safety monitoring board of the ALL-
HAT trial recommended discontinuance of
the doxazosin arm.
There are other characteristics of blood
pressure drugs, other than their effect on so
called hard end points, that are as important
as getting blood pressure controlled. These
include cost, profile of adverse effects, ease
of use (once daily versus several daily doses),
and interactions with other drug agents. In
all aspects, thiazide type diuretics come up
tops as first line agents. This was amply
shown in the systolic hypertension in the
elderly programme (SHEP) and Medical
Research Council studies, in which thiazide
diuretics were associated with a greater than
40% reduction in the risk of stroke in
patients with isolated systolic hypertension;
these studies were conducted and com-
pleted more than a decade ago.3 4 ALLHAT
also showed the differences in tolerability
between agents, and the particular difficulty
in controlling blood pressure to target
values especially with angiotensin convert-
ing enzyme inhibitors in black patients.
In choosing a therapeutic agent to lower
blood pressure and reduce cardiovascular
risk, one must look at not only the blood
pressure lowering effect but also important
clinical end points that we are aiming to
prevent, as well as issues such as cost and
tolerability.
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Thiazides with your pension?
Editor—As Williams says in his editorial,
the antihypertensive and lipid lowering
treatment to prevent heart attack trial (ALL-
HAT) reaffirms the use of thiazide diuretics
as a first line treatment for the older popula-
tion with hypertension.1 But what about
older patients who are not hypertensive?
For more than 20 years we have seen
numerous studies that indicate that thiazide
diuretics, in the usual antihypertensive
doses, preserve bone mineralisation,2 and,
importantly, the use of thiazide diuretics
seems to be associated with a 30-40% reduc-
tion in the risk of hip fracture.3 4
However, if we are to start our thiazide at
the same time we pick up our pension then
we really need a randomised controlled trial.
It is perverse that we do not have such a
study because thiazides are so cheap. If
modern health care is to maximise its
potential, then healthcare agencies need to
be prepared to pick up the costs for
appropriate research and relicensing of
older drugs, and not just the costs of the
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patented drugs from which pharmaceutical
companies calculate they can make a profit.
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Identifying malnourished
children may not be easy
Editor—Bahn et al propose to use the
World Health Organization’s criteria for
diagnosing malnutrition,1 which include cal-
culating Z scores for weight for height, and
height for age.
Rural hospitals in resource poor areas
are often severely understaffed but at the
same time have high admission rates of
especially small children. The amount of
strain that measuring the heights of all
admitted children puts on the medical and
nursing staff should not be underestimated.
Measuring is considered to be too time con-
suming and of little value in establishing the
diagnosis and is therefore often left out in
the assessment of the child.
In many hospitals in rural Kenya malnu-
trition is diagnosed only on clinical grounds
such as weight, presence of pedal oedema,
and discolouration of the hair. To try to
measure the correlation between clinical
diagnosis and more objective assessment
through anthropometric indices, we con-
ducted a study in Misikhu Mission Hospital
in western Kenya.2 For five months all
admitted children under the age of 5 years
(n=1130), had their anthropometric indices
calculated by using Epi-Info software and
then compared with the clinical diagnosis.
Sixteen per cent of the admitted children
were wasted (weight for height score < 2SD
below the mean), and an additional 16% were
stunted (height for age score < 2SD below
the mean). Just 14% of the wasted children
and 11% of the stunted children were identi-
fied by clinical assessment as having mal-
nutrition and would have got appropriate
treatment when only clinical variables were
taken into account at the time of diagnosis.
Measuring height cannot be left out
when assessing the possible presence of
malnutrition in a child.Once the diagnosis is
made, the guidelines mentioned by Bahn et
al should help the doctor in the actual treat-
ment of malnourished children.
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Skin scarring: new insights
may make adjustment easier
Editor—Skin scarring is a clinical problem
that can cause many psychological and
social difficulties—some as a result of the
cause of the scarring (for example, trauma),
some related to the effects (for example,
itching), and many to the appearance of the
scar itself. In the review by Bayat et al their
argument that a decision to treat will depend
on site, symptoms, severity of functional
impairment, and stigma would be enhanced
by the inclusion of two crucial insights from
recent psychological literature, insights that
can make it much easier for patients to
adjust to these problems.1
Firstly, much research has now con-
firmed that the seriousness of psychosocial
sequelae is not positively correlated with the
severity, size, or location of scarring.2 It is
therefore important in the clinical examina-
tion and assessment process that doctors do
not make assumptions about the psycho-
social impact of scarring—it is important to
ask patients about how self conscious they
feel, for example, and how noticeable they
feel the scar is to others because these
factors are likely to be more predictive of
distress.3
Secondly, recognising that even with the
skills of surgeons and others, scars cannot yet
be made to disappear has prompted new
psychosocial interventions to be developed
for patients distressed by disfigurements of
any kind, including scarring, to their face,
hands, and body. These have focused on the
strengthening of self esteem and communi-
cation skills (so as to manage the reactions of
other people) and are available in various for-
mats including in self-help guides produced
by a charity, Changing Faces (for example,
Everybody’s Staring at Me! How to Communicate
When You Have an Unusual Face). These new
interventions are becoming known to psy-
chologists across the NHS and can be
delivered by individual psychologists or
through a centralised referral unit such as the
outlook unit at Frenchay Hospital, Bristol.4
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“Author pays” as new science
publishing model
Several models of scientific publishing
are likely
Editor—According to Delamothe, a con-
sensus is emerging on how the internet will
change the economics of scientific publish-
ing.1 As far as I am aware no journal relying
solely on charging authors for online publi-
cation has yet managed to derive sufficient
revenue from this model to meet its running
costs.
Our approach at Oxford University
Press is to maximise the dissemination of
our online journals by adapting the tra-
ditional subscription model to extend online
access to groups of institutions, companies,
whole states, or countries. We also offer free
online access to the poorest developing
countries, and we participate in archives
such as those provided by PubMed Central
and HighWire Press. In addition, we are
experimenting with other pricing models,
including charging authors for publication
and providing “free” online versions subsi-
dised from print revenues or by advertising.
I think that, although the virtual world is
changing the economics of scientific pub-
lishing, in the real world no single model is
likely to meet the needs of every author or
reader. Open access journals funded by
author charges may eventually prove to be
the economic model of choice in some
cases, but most journals, unless they also
benefit from grants or subsidies, will need to
rely on a mixture of economic models to
continue to support the costs of online
publication.
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Cautious welcome is in order
Editor—I welcome the development out-
lined by Delamothe that authors should pay
for publication of their work, while appreci-
ating the difficulties many journals face in
providing free access, as well as the authors’
desire to publish and retain copyright of
their work.1 However, my welcome is
qualified.
Firstly, Delamothe talks of the hope that
agencies funding the original research will
agree to foot the authors’ bill. What
happens with authors who do not have such
a luxury?
Secondly, what effect will the authors
pay model have on research from develop-
ing countries reaching the wider audience it
craves and deserves? Such research, of
course, is already disadvantaged on many
fronts.
Ahmad Risk editor
Health Informatics Europe, Brighton BN3 2JD
risk@cybermedic.org
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It’s time to wake up to the hidden
agendas of free journals
Editor—The concept of free online jour-
nals seems too good to be true.1 2 Certain
hidden agendas need attention.
Firstly, journals are essentially asking the
authors to ask their sponsors to pay for the
cost of publication. Industries would grab
such opportunities to publish their works.
Journals might then be flooded with
publications sponsored by industry. Such
publications would convey the conclusions
favourable to the industry, and positive
results would be published more often than
negative ones.3 Researchers’ growing
dependence on the industry, accompanied
by a decline in support from the govern-
ment, makes this a distinct probability.3
Secondly, researchers who do not have
major sponsors would miss out on publica-
tions in journals of their choice.
Thirdly, the fact that industry would pay
for the cost of publication means two tier
journals would be produced. The so called
free journal might in effect be the proxy
mouthpiece of the industry, which is exempli-
fied by the existing notion that free journals
are simply vehicles for advertisements.4
Fourthly, the “paid” journals would
struggle to cater in the conventional way.
Worse, if the authors have to reach into their
pockets to pay (in the absence of sponsor-
ship) £936 ($1500, €1460) per article, it
would be interesting to see how many
papers would be published. In such an even-
tuality only the “quality” journals would be
able to survive. Paradoxically, given the
current non-competitive nature of journals,
some may view this as a blessing in disguise.5
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“Free” medical publishing
venture gets under way
Open access monopoly may threaten
smaller journals
Editor—I am editor and publisher of a
small but (in my opinion) high quality open
access journal (Journal of Medical Internet
Research (JMIR)) (www.jmir.org), which has
been open access since its inception in 1999
and which recently introduced an article
processing fee of $500 (£306; €463). I there-
fore cannot help feeling threatened by a
powerful organisation such as the Public
Library of Science (PLoS), with a backing of
$9m and influential people at the top.1
I wonder why—if you have $9m—you still
need to charge the authors three times more
than we charge for an article, although we
do not have any funding for the journal
(except $500 mini-grants from the Soros
Foundation, for fee waivers for needy
authors). On the other hand, it is good that
the PLoS fee is so high—otherwise smaller
open access journals such as ours that need
to charge a fee would be in trouble. PLoS
might accidentally destroy what it means to
foster: open access journals.
I wish foundations and scientists (peer
reviewing and writing for journals) sup-
ported groups of scientists taking publishing
into their own hands by using the web,
rather than supporting megalomaniac
organisations that aim to centralise and
dominate. Open access has been made pos-
sible through the internet, and the internet
is a wonderful decentralised medium. Let’s
keep it that way. We are just trying to free
ourselves from the oligarchy of large
publishing houses. Why do we need to
create a new mega-organisation that tries to
monopolise publishing? Establishing an
online journal, setting up a peer review sys-
tem, and getting the journal indexed in bib-
liographic databases is not rocket science.
The group of editors that runs JMIR has
decided that it needs neither BioMed
Central nor PLoS for that.
PLoS should stay what it was—an
advocacy group—but not enter into a
competition with existing open access
journals. If PLoS wants to use the $9m
wisely, it should use it to support existing
open access journals rather than competing
with them.
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Publishing is getting expensive
Editor—Wow—£936 ($1530; €1415) to
have your article published—that’s expen-
sive.1 It should cost a reasonably efficient
organisation about £100 to peer review an
article (www.carnall.org/peerrev.htm). Even
if a subeditor takes another day or two to get
the article in shape this wouldn’t come to
£800. For £936 you could buy a webserver
and a couple of years of internet connection,
and do it yourself.
Harold Varmus must be on a good salary.
Or perhaps it is being priced to fail? Oh well.
One way or another knowledge will out.
Douglas Carnall general practitioner
London E8 1AJ
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Sore throats, why the dilemma?
Editor—With reference to the article by
Kumar et al, I find it hard to believe that the
argument still goes on about the treatment
of sore throats.1 If I had the energy I would
dig up the articles to support the following
statements.
Firstly, the only probably treatable
organism in the throat is streptococcus,
virtually all else is viral.
Secondly, during the second world war
the US government decided that the only
sensible treatment was to give all troops
complaining of a sore throat an injection of
penicillin. They were unlikely to complete a
10 day course of antibiotics orally, and the
risk of anaphylaxis was less than the risk of a
war injury.
Thirdly, multiple studies show that it is
very difficult to get anyone to complete a 10
day course of penicillin.
Fourthly, drug resistance is on the rise
due to overuse of antibiotics.
Fifthly, rapid tests for streptococci have
been available for over 10 years. They can
give reliable results within minutes and have
been standard practice in the United States
for ages but very unpopular with UK
authorities. Could it be because the
penicillin is cheaper than the test?
Sixthly, there is only weak evidence that
treating strep throat with antibiotics hastens
resolution of symptoms, but we would like to
believe that it will reduce the presence of
secondary complications such as rheumatic
fever and quinsy (but not glomerulo-
nephritis).
If you are determined to reduce the
overuse of antibiotics either do a culture and
wait 24-48 hours to treat positive results or
do a rapid strep test and treat patients whose
results are positive. Either strategy will
prevent complications and would be equally
efficacious in relieving symptoms. In the
developing world or inner cities, where only
relatively ill patients come to the doctor and
compliance is difficult, an injection of
penicillin or short course of azithromycin is
sensible. Once the patients realise that the
complaint of sore throat is greeted with an
injection they will be very judicious of their
use of the doctor’s services.
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